210 related articles for article (PubMed ID: 31093341)
41. Salivary Gland Cancers: Biology and Systemic Therapy.
Goyal G; Mehdi SA; Ganti AK
Oncology (Williston Park); 2015 Oct; 29(10):773-80. PubMed ID: 26470903
[TBL] [Abstract][Full Text] [Related]
42. Salivary gland malignancies in children.
Yoshida EJ; García J; Eisele DW; Chen AM
Int J Pediatr Otorhinolaryngol; 2014 Feb; 78(2):174-8. PubMed ID: 24332197
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer.
Rack S; Feeney L; Hapuarachi B; Adderley H; Woodhouse L; Betts G; Burghel GJ; Harrington KJ; Metcalf R
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267442
[TBL] [Abstract][Full Text] [Related]
44. Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Vattemi E; Graiff C; Sava T; Pedersini R; Caldara A; Mandarà M
Expert Rev Anticancer Ther; 2008 Mar; 8(3):393-402. PubMed ID: 18366287
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
[TBL] [Abstract][Full Text] [Related]
46. The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative.
Morand GB; Eskander A; Fu R; de Almeida J; Goldstein D; Noroozi H; Hosni A; Seikaly H; Tabet P; Pyne JM; Matthews TW; Dort J; Nakoneshny S; Christopoulos A; Bahig H; Johnson-Obaseki S; Hua N; Gaudet M; Jooya A; Nichols A; Laxague F; Cecchini M; Du J; Shapiro J; Karam I; Dziegielewski PT; Hanubal K; Erovic B; Grasl S; Davies J; Monteiro E; Gete M; Witterick I; Sadeghi N; Richardson K; Shenouda G; Maniakas A; Landry V; Gupta M; Zhou K; Mlynarek AM; Pusztaszeri M; Sultanem K; Hier MP
Cancer; 2023 Oct; 129(20):3263-3274. PubMed ID: 37401841
[TBL] [Abstract][Full Text] [Related]
47. EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.
Suzuki S; Dobashi Y; Minato H; Tajiri R; Yoshizaki T; Ooi A
Virchows Arch; 2012 Sep; 461(3):271-82. PubMed ID: 22828828
[TBL] [Abstract][Full Text] [Related]
48. Androgen Receptor Signaling in Salivary Gland Cancer.
Dalin MG; Watson PA; Ho AL; Morris LG
Cancers (Basel); 2017 Feb; 9(2):. PubMed ID: 28208703
[TBL] [Abstract][Full Text] [Related]
49. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
[TBL] [Abstract][Full Text] [Related]
50. [Systemic treatments of metastatic or locally recurrent adenoid cystic carcinoma of the head and neck, a systematic review].
Cherifi F; Rambeau A; Johnson A; Florescu C; Géry B; Babin E; Thariat J
Bull Cancer; 2019 Oct; 106(10):923-938. PubMed ID: 31324333
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H
J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361
[TBL] [Abstract][Full Text] [Related]
52. The Therapeutic Landscape of Salivary Gland Malignancies-Where Are We Now?
Cleymaet R; Vermassen T; Coopman R; Vermeersch H; De Keukeleire S; Rottey S
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499216
[TBL] [Abstract][Full Text] [Related]
53. Management and outcome of patients with malignant salivary gland tumors.
Bell RB; Dierks EJ; Homer L; Potter BE
J Oral Maxillofac Surg; 2005 Jul; 63(7):917-28. PubMed ID: 16003616
[TBL] [Abstract][Full Text] [Related]
54. New concepts of personalized therapy in salivary gland carcinomas.
Keller G; Steinmann D; Quaas A; Grünwald V; Janssen S; Hussein K
Oral Oncol; 2017 May; 68():103-113. PubMed ID: 28325631
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies.
Kadletz L; Aumayr K; Heiduschka G; Schneider S; Enzenhofer E; Lill C
Eur Arch Otorhinolaryngol; 2017 Jan; 274(1):467-475. PubMed ID: 27470117
[TBL] [Abstract][Full Text] [Related]
56. Recurrent malignant salivary gland neoplasms.
Rodriguez-Bigas MA; Sako K; Razack MS; Shedd DP; Bakamjian VY; Castillo NB; Rao U
J Surg Oncol; 1989 Oct; 42(2):92-5. PubMed ID: 2796352
[TBL] [Abstract][Full Text] [Related]
57. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
[TBL] [Abstract][Full Text] [Related]
58. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target.
Clauditz TS; Gontarewicz A; Lebok P; Tsourlakis MC; Grob TJ; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Oral Oncol; 2012 Oct; 48(10):991-996. PubMed ID: 22694907
[TBL] [Abstract][Full Text] [Related]
60. HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients.
Cavalieri S; Nuzzolese I; Ottini A; Bergamini C; Resteghini C; Colombo E; Alfieri S; Quattrone P; Calareso G; Iacovelli NA; Franceschini M; Licitra L
Front Oncol; 2022; 12():1096068. PubMed ID: 36733354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
